Nucleic acid-sensing TLRs and autoimmunity: Novel insights from structural and cell biology

Immunological Reviews

Volumn 269, Issue 1, 2016, Pages 60-75

  Pelka, Karin ^a   Shibata, Takuma ^b,c   Miyake, Kensuke ^b   Latz, Eicke ^a,d,e  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Autoimmunity; Nucleic acid sensing; TLR; UNC93B1

Indexed keywords

DEOXYRIBONUCLEASE; DEOXYRIBONUCLEASE I; DEOXYRIBONUCLEASE II; DEOXYRIBONUCLEASE III; DNA; INTERFERON; NUCLEASE; NUCLEIC ACID; RIBONUCLEASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNITY; CELL COMPARTMENTALIZATION; CELL MATURATION; CELL MIGRATION; CELL STRUCTURE; CRYSTAL STRUCTURE; CYTOLOGY; ENDOSOME; HUMAN; INFECTION; LYSOSOME; NONHUMAN; PHAGOSOME; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TISSUE INJURY; ANIMAL; HOMEOSTASIS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; METABOLISM;

ANIMALS; AUTOIMMUNITY; HOMEOSTASIS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; NUCLEIC ACIDS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84950109725     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12375     Document Type: Article

References (176)

1. Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989;54(Pt 1):1-13.
2. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
3. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev 2009;227:75-86.
4. Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 2007;220:251-269.
5. Barbalat R, Ewald SE, Mouchess ML, Barton GM. Nucleic acid recognition by the innate immune system. Annu Rev Immunol 2011;29:185-214.
6. Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol 2014;32:461-488.
7. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-376.
8. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-995.
9. Yarovinsky F, et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 2005;308:1626-1629.
10. Koblansky AA, et al. Recognition of profilin by toll-like receptor 12 is critical for host resistance to Toxoplasma gondii. Immunity 2013;38:119-130.
11. Raetz M, et al. Cooperation of TLR12 and TLR11 in the IRF8-dependent IL-12 response to Toxoplasma gondii profilin. J Immunol 2013;191:4818-4827.
12. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-738.
13. Diebold SS. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-1531.
14. Heil F, et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004;303:1526-1529.
15. Oldenburg M, et al. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science 2012;337:1111-1115.
16. Hidmark A, von Saint Paul A, Dalpke AH. Cutting edge: TLR13 is a receptor for bacterial RNA. J Immunol 2012;189:2717-2721.
17. Hemmi H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745.
18. Bauer S, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001;98:9237-9242.
19. Hemmi H, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200.
20. Jurk M, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002;3:499.
21. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11:373-384.
22. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321:209-213.
23. Sved J, Bird A. The expected equilibrium of the CpG dinucleotide in vertebrate genomes under a mutation model. Proc Natl Acad Sci USA 2015;87:4692-4696.
24. Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 1988;140:2197-2200.
25. Jacobs BL, Langland JO. When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology 1996;219:339-349.
26. Barrat FJ. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131-1139.
27. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol 2006;7:49-56.
28. Bernard JJ, et al. Ultraviolet radiation damages self noncoding RNA and is detected by TLR3. Nat Med 2012;18:1286-1290.
29. Liu L, et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 2008;320:379-381.
30. Tanji H, Ohto U, Shibata T, Miyake K, Shimizu T. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. Science 2013;339:1426-1429.
31. Tanji H, et al. Toll-like receptor 8 senses degradation products of single-stranded RNA. Nat Struct Mol Biol 2015;22:109-115.
32. Ohto U, et al. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. Nature 2015;520:702-705.
33. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Möröy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 2000;25:177-181.
34. Yoshida H, Okabe Y, Kawane K, Fukuyama H, Nagata S. Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. Nat Immunol 2005;6:49-56.
35. Kawane K, et al. Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 2006;443:998-1002.
36. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008;134:587-598.
37. Lan YY, Londoño D, Bouley R, Rooney MS, Hacohen N. Dnase2a deficiency uncovers lysosomal clearance of damaged nuclear DNA via autophagy. Cell Rep 2014;9:180-192.
38. Yasutomo K, et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 2001;28:313-314.
39. Rice G, et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet 2007;81:713-725.
40. Lande R, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007;449:564-569.
41. Mouchess ML, et al. Transmembrane mutations in Toll-like receptor 9 bypass the requirement for ectodomain proteolysis and induce fatal inflammation. Immunity 2011;35:721-732.
42. Ewald SE, et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008;456:658-662.
43. Yi AK, Tuetken R, Redford T, Waldschmidt M, Kirsch J, Krieg AM. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol 1998;160:4755-4761.
44. Häcker H, et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 1998;17:6230-6240.
45. Lee J, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA 2003;100:6646-6651.
46. Heil F, et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003;33:2987-2997.
47. de Bouteiller O, et al. Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J Biol Chem 2005;280:38133-38145.
48. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011;186:4794-4804.
49. Leonard JN, et al. The TLR3 signaling complex forms by cooperative receptor dimerization. Proc Natl Acad Sci USA 2008;105:258-263.
50. Rutz M, et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 2004;34:2541-2550.
51. Manzel L, Macfarlane DE. Lack of immune stimulation by immobilized CpG-oligodeoxynucleotide. Antisense Nucleic Acid Drug Dev 1999;9:459-464.
52. Ahmad-Nejad P, Häcker H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002;32:1958-1968.
53. Latz E, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004;5:190-198.
54. Lee H-K, Dunzendorfer S, Soldau K, Tobias PS. Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. Immunity 2006;24:153-163.
55. Bartholomeu DC, et al. Recruitment and endo-lysosomal activation of TLR9 in dendritic cells infected with Trypanosoma cruzi. J Immunol 2008;181:1333-1344.
56. Kasperkovitz PV, Cardenas ML, Vyas JM. TLR9 is actively recruited to Aspergillus fumigatus phagosomes and requires the N-terminal proteolytic cleavage domain for proper intracellular trafficking. J Immunol 2010;185:7614-7622.
57. Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science 2007;315:1398-1401.
58. Henault J, et al. Noncanonical autophagy is required for type I interferon secretion in response to DNA-immune complexes. Immunity 2012;37:986-997.
59. Chaturvedi A, Dorward D, Pierce SK. The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity 2008;28:799-809.
60. Honda K, et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005;434:1035-1040.
61. Guiducci C. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med 2006;203:1999-2008.
62. Sasai M, Linehan MM, Iwasaki A. Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3. Science 2010;329:1530-1534.
63. Chan MP, et al. DNase II-dependent DNA digestion is required for DNA sensing by TLR9. Nat Commun 2014;6:5853.
64. Braulke T, Bonifacino JS. Sorting of lysosomal proteins. Biochim Biophys Acta 2009;1793:605-614.
65. Häcker H, et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 2005;439:204-207.
66. Blasius AL, et al. Slc15a4, AP-3, and Hermansky-Pudlak syndrome proteins are required for Toll-like receptor signaling in plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2010;107:19973-19978.
67. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011;34:637-650.
68. Mercer J, Schelhaas M, Helenius A. Virus entry by endocytosis. Annu Rev Biochem 2010;79:803-833.
69. Gruenberg J, van der Goot FG. Mechanisms of pathogen entry through the endosomal compartments. Nat Rev Mol Cell Biol 2006;7:495-504.
70. Ewald SE, Engel A, Lee J, Wang M, Bogyo M, Barton GM. Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. J Exp Med 2011;208:643-651.
71. Garcia-Cattaneo A, et al. Cleavage of Toll-like receptor 3 by cathepsins B and H is essential for signaling. Proc Natl Acad Sci USA 2012;109:9053-9058.
72. Qi R, Singh D, Kao CC. Proteolytic processing regulates Toll-like receptor 3 stability and endosomal localization. J Biol Chem 2012;287:32617-32629.
73. Hipp MM, et al. Processing of human Toll-like receptor 7by furin-like proprotein convertases is required for its accumulation and activity in endosomes. Immunity 2013;39:711-721.
74. Ishii N, Funami K, Tatematsu M, Seya T, Matsumoto M. Endosomal localization of TLR8 confers distinctive proteolytic processing on human myeloid cells. J Immunol 2014;193:5118-5128.
75. Park B, Brinkmann MM, Spooner E, Lee CC, Kim Y-M, Ploegh HL. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat Immunol 2008;9:1407-1414.
76. Sepulveda FE, et al. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity 2009;31:737-748.
77. Matsumoto F, et al. Cathepsins are required for Toll-like receptor 9 responses. Biochem Biophys Res Commun 2008;367:693-699.
78. Onji M, et al. An essential role for the N-terminal fragment of Toll-like receptor 9 in DNA sensing. Nat Commun 2013;4:1949.
79. Peter ME, Kubarenko AV, Weber ANR, Dalpke AH. Identification of an N-terminal recognition site in TLR9 that contributes to CpG-DNA-mediated receptor activation. J Immunol 2009;182:7690-7697.
80. Lee S, Kang D, Ra EA, Lee TA, Ploegh HL, Park B. Negative self-regulation of TLR9 signaling by its N-terminal proteolytic cleavage product. J Immunol 2014;193:3726-3735.
81. Murakami Y, et al. Roles of the cleaved N-terminal TLR3 fragment and cell surface TLR3 in double-stranded RNA sensing. J Immunol 2014;193:5208-5217.
82. Kanno A, et al. Essential role for Toll-like receptor 7 (TLR7)-unique cysteines in an intramolecular disulfide bond, proteolytic cleavage and RNA sensing. Int Immunol 2013;25:413-422.
83. Hipp MM, Shepherd D, Booth S, Waithe D, Reis e Sousa C, Cerundolo V. The processed amino-terminal fragment of human TLR7 acts as a chaperone to direct human TLR7 into endosomes. J Immunol 2015;194:5417-5425.
84. Toscano F, et al. Cleaved/associated TLR3 represents the primary form of the signaling receptor. J Immunol 2013;190:764-773.
85. Choe J, Kelker MS, Wilson IA. Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science 2005;309:581-585.
86. Bell JK, et al. The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc Natl Acad Sci USA 2005;102:10976-10980.
87. Latz E, et al. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 2007;8:772-779.
88. Pawaria S, et al. Cutting edge: DNase II deficiency prevents activation of autoreactive B cells by double-stranded DNA endogenous ligands. J Immunol 2015;194:1403-1407.
89. Kerkmann M, et al. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells. J Biol Chem 2005;280:8086-8093.
90. Vollmer J, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004;34:251-262.
91. Leifer CA, Kennedy MN, Mazzoni A, Lee C, Kruhlak MJ, Segal DM. TLR9 is localized in the endoplasmic reticulum prior to stimulation. J Immunol 2004;173:1179-1183.
92. Avalos AM, et al. Cell-specific TLR9 trafficking in primary APCs of transgenic TLR9-GFP mice. J Immunol 2013;190:695-702.
93. Li X, Saitoh SI, Shibata T, Tanimura N, Fukui R, Miyake K. Mucolipin 1 positively regulates TLR7 responses in dendritic cells by facilitating RNA transportation to lysosomes. Int Immunol 2015;27:83-94.
94. Itoh H, et al. UNC93B1 physically associates with human TLR8 and regulates TLR8-mediated signaling. PLoS ONE 2011;6:e28500.
95. Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun 2002;293:1364-1369.
96. Matsumoto M, et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 2003;171:3154-3162.
97. Funami K. The cytoplasmic "linker region" in Toll-like receptor 3 controls receptor localization and signaling. Int Immunol 2004;16:1143-1154.
98. Johnsen IB, et al. Toll-like receptor 3 associates with c-Src tyrosine kinase on endosomes to initiate antiviral signaling. EMBO J 2006;25:3335-3346.
99. Nishiya T, DeFranco AL. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J Biol Chem 2004;279:19008-19017.
100. Kanno A, et al. Targeting cell surface TLR7 for therapeutic intervention in autoimmune diseases. Nat Commun 2015;6:6119.
101. Dasari P, Nicholson IC, Hodge G, Dandie GW, Zola H. Expression of toll-like receptors on B lymphocytes. Cell Immunol 2005;236:140-145.
102. Baiyee EE, et al. Expression and function of Toll-like receptor 9 in severely injured patients prone to sepsis. Clin Exp Immunol 2006;145:456-462.
103. Eaton-Bassiri A, et al. Toll-like receptor 9 can be expressed at the cell surface of distinct populations of tonsils and human peripheral blood mononuclear cells. Infect Immun 2004;72:7202-7211.
104. Saikh KU, Kissner TL, Sultana A, Ruthel G, Ulrich RG. Human monocytes infected with Yersinia pestis express cell surface TLR9 and differentiate into dendritic cells. J Immunol 2004;173:7426-7434.
105. Lindau D, et al. Primary blood neutrophils express a functional cell surface Toll-like receptor 9. Eur J Immunol 2013;43:2101-2113.
106. Lee J, et al. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 2006;8:1327-1336.
107. Schmausser B, et al. Expression and subcellular distribution of toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol 2004;136:521-526.
108. Shintani Y, et al. TLR9 mediates cellular protection by modulating energy metabolism in cardiomyocytes and neurons. Proc Natl Acad Sci USA 2013;110:5109-5114.
109. Trowbridge IS, Collawn JF, Hopkins CR. Signal-dependent membrane protein trafficking in the endocytic pathway. Annu Rev Cell Biol 1993;9:129-161.
110. Lee BL, et al. UNC93B1 mediates differential trafficking of endosomal TLRs. Elife 2013;2:e00291.
111. Tabeta K, et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 2006;7:156-164.
112. Kim Y-M, Brinkmann MM, Paquet M-E, Ploegh HL. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature 2008;452:234-238.
113. Brinkmann MM, Spooner E, Hoebe K, Beutler B, Ploegh HL, Kim Y-M. The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J Cell Biol 2007;177:265-275.
114. Casrouge A, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006;314:308-312.
115. Lafaille FG, et al. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature 2012;491:769-773.
116. Pelka K, et al. Cutting edge: the UNC93B1 tyrosine-based motif regulates trafficking and TLR responses via separate mechanisms. J Immunol 2014;193:3257-3261.
117. Fukui R, et al. Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing. J Exp Med 2009;206:1339-1350.
118. Fukui R, et al. Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking. Immunity 2011;35:69-81.
119. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006;25:417-428.
120. Huh JW, et al. UNC93B1 is essential for the plasma membrane localization and signaling of Toll-like receptor 5. Proc Natl Acad Sci USA 2014;111:7072-7077.
121. Kim J, et al. Acidic amino acid residues in the juxtamembrane region of the nucleotide-sensing TLRs are important for UNC93B1 binding and signaling. J Immunol 2013;190:5287-5295.
122. Pohar J, Pirher N, Bencina M, Mancek-Keber M, Jerala R. The role of UNC93B1 protein in surface localization of TLR3 receptor and in cell priming to nucleic acid agonists. J Biol Chem 2013;288:442-454.
123. + channel that coordinates muscle contraction in Caenorhabditis elegans. J Neurosci 2003;23:9133-9145.
124. Law CJ, Maloney PC, Wang D-N. Ins and outs of major facilitator superfamily antiporters. Annu Rev Microbiol 2008;62:289-305.
125. Deguine J, Lee BL, Newman ZR, Barton GM. No antigen-presentation defect in Unc93b1(3d/3d) (3d) mice. Nat Immunol 2013;14:1101-1102.
126. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006;6:823-835.
127. Wang Y, Swiecki M, McCartney SA, Colonna M. dsRNA sensors and plasmacytoid dendritic cells in host defense and autoimmunity. Immunol Rev 2011;243:74-90.
128. Flutter B, Nestle FO. TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis. Eur J Immunol 2013;43:3138-3146.
129. Diana J, et al. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med 2012;19:65-73.
130. Rachmilewitz D, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002;122:1428-1441.
131. Katakura K, Lee J, Rachmilewitz D, Li G, Eckmann L, Raz E. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest 2005;115:695-702.
132. Hall JA, et al. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity 2008;29:637-649.
133. Isnardi I, et al. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 2008;29:746-757.
134. Casanova J-L, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol 2011;29:447-491.
135. Zhou X-J, Lv J-C, Cheng W-R, Yu L, Zhao M-H, Zhang H. Association of TLR9 gene polymorphisms with lupus nephritis in a Chinese Han population. Clin Exp Rheumatol 2010;28:397-400.
136. Vaughn SE, Kottyan LC, Munroe ME, Harley JB. Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways. J Leukoc Biol 2012;92:577-591.
137. Cui Y, Sheng Y, Zhang X. Genetic susceptibility to SLE: recent progress from GWAS. J Autoimmun 2013;41:25-33.
138. Wang C-M, et al. Genetic variations in Toll-like receptors (TLRs 3/7/8) are associated with systemic lupus erythematosus in a Taiwanese population. Sci Rep 2014;4:3792.
139. Zhang J, Zhu Q, Meng F, Lei H, Zhao Y. Association study of TLR-9 polymorphisms and systemic lupus erythematosus in northern Chinese Han population. Gene 2014;533:385-388.
140. Laska MJ, et al. Polymorphisms within Toll-like receptors are associated with systemic lupus erythematosus in a cohort of Danish females. Rheumatology 2014;53:48-55.
141. Lee YH, Bae SC, Song GG. Meta-analysis demonstrates association between TLR polymorphisms and rheumatoid arthritis. Genet Mol Res 2013;12:328-334.
142. Laska MJ, et al. A non-synonymous single-nucleotide polymorphism in the gene encoding Toll-like receptor 3 (TLR3) is associated with sero-negative rheumatoid arthritis (RA) in a Danish population. BMC Res Notes 2014;7:716.
143. Lee YH, Bae S-C, Kim J-H, Song GG. Toll-like receptor polymorphisms and rheumatoid arthritis: a systematic review. Rheumatol Int 2013;34:111-116.
144. Dubois PCA, et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 2010;42:295-302.
145. Demaria O, et al. TLR8 deficiency leads to autoimmunity in mice. J Clin Invest 2010;120:3651-3662.
146. Guiducci C, et al. RNA recognition by human TLR8 can lead to autoimmune inflammation. J Exp Med 2013;210:2903-2919.
147. Desnues B, et al. TLR8 on dendritic cells and TLR9 on B cells restrain TLR7-mediated spontaneous autoimmunity in C57BL/6 mice. Proc Natl Acad Sci USA 2014;111:1497-1502.
148. Sharma S, et al. Suppression of systemic autoimmunity by the innate immune adaptor STING. Proc Natl Acad Sci USA 2015;112:E710-E717.
149. Li S, Wang L, Berman M, Kong Y-Y, Dorf ME. Mapping a dynamic innate immunity protein interaction network regulating type I interferon production. Immunity 2011;35:426-440.
150. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-607.
151. Ahn J, Gutman D, Saijo S, Barber GN. STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci USA 2012;109:19386-19391.
152. Rossol M, et al. Homozygosity for DNASE2 single nucleotide polymorphisms in the 5′-regulatory region is associated with rheumatoid arthritis. Ann Rheum Dis 2009;68:1498-1503.
153. Baum R, et al. Cutting edge: AIM2 and endosomal TLRs differentially regulate arthritis and autoantibody production in DNase II-deficient mice. J Immunol 2015;194:873-877.
154. Jakobs C, Perner S, Hornung V. AIM2 drives joint inflammation in a self-DNA triggered model of chronic polyarthritis. PLoS ONE 2015;10:e0131702.
155. Gall A, et al. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 2012;36:120-131.
156. Gehrke N, et al. Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity 2013;39:482-495.
157. Li J. Genetic dissection of systemic autoimmune disease in Nrf2-deficient mice. Physiol Genomics 2004;18:261-272.
158. Lunec J, Herbert K, Blount S, Griffiths HR, Emery P. 8-Hydroxydeoxyguanosine. A marker of oxidative DNA damage in systemic lupus erythematosus. FEBS Lett 1994;348:131-138.
159. Fazzi E, et al. Aicardi-Goutieres syndrome, a rare neurological disease in children: a new autoimmune disorder?. Autoimmun Rev 2013;12:506-509.
160. Eckard SC, et al. The SKIV2L RNA exosome limits activation of the RIG-I-like receptors. Nat Immunol 2014;15:839-845.
161. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13:552-559.
162. Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 2008;223:271-283.
163. Connolly DJ, O'Neill LA. New developments in Toll-like receptor targeted therapeutics. Curr Opin Pharmacol 2012;12:510-518.
164. Sun S, Rao NL, Venable J, Thurmond R, Karlsson L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets 2007;6:223-235.
165. Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 2007;18:1721-1731.
166. Zhu F-G, et al. A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice. Autoimmunity 2013;46:419-428.
167. Jiang W, et al. A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis. J Invest Dermatol 2013;133:1777-1784.
168. Sarvestani ST, Williams BRG, Gantier MP. Human Toll-like receptor 8 can be cool too: implications for foreign RNA sensing. J Interferon Cytokine Res 2012;32:350-361.
169. Barchet W, Wimmenauer V, Schlee M, Hartmann G. Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr Opin Immunol 2008;20:389-395.
170. Dynavax. Dynavax Regains Full Rights to Investigational TLR7/9 Inhibitor DV1179 Following Expiration of Collaboration with GSK. 2014:1.
171. Idera Pharmaceuticals. Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of IMO-8400. 2014:1-3.
172. Idera Pharmaceuticals. Idera Pharmaceuticals Announces Positive Top-line Results from Phase 2 Trial of IMO-3100 in Patients with Moderate-to-Severe Plaque Psoriasis. 2012:1-4.
173. Musch E, et al. Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity. Inflamm Bowel Dis 2013;19:283-292.
174. ® in the Treatment of Moderate to Severe Ulcerative Colitis. 2014:1-2.
175. Sandgren S, et al. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. J Biol Chem 2004;279:17951-17956.
176. Ukkonen P, Lewis V, Marsh M, Helenius A, Mellman I. Transport of macrophage Fc receptors and Fc receptor-bound ligands to lysosomes. J Exp Med 1986;163:952-971.